Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Inventory (2016 - 2025)

IGC Pharma (IGC) has disclosed Inventory for 14 consecutive years, with $47000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Inventory fell 7.84% to $47000.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $47000.0, a 7.84% decrease, with the full-year FY2025 number at $1.4 million, up 2515.38% from a year prior.
  • Inventory was $47000.0 for Q2 2025 at IGC Pharma, down from $1.4 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $2.6 million in Q3 2023 to a low of $15000.0 in Q2 2023.
  • A 5-year average of $510666.7 and a median of $55000.0 in 2022 define the central range for Inventory.
  • Peak YoY movement for Inventory: plummeted 98.33% in 2024, then skyrocketed 2515.38% in 2025.
  • IGC Pharma's Inventory stood at $511000.0 in 2021, then crashed by 89.24% to $55000.0 in 2022, then soared by 4692.73% to $2.6 million in 2023, then tumbled by 98.37% to $43000.0 in 2024, then grew by 9.3% to $47000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Inventory are $47000.0 (Q2 2025), $1.4 million (Q1 2025), and $43000.0 (Q4 2024).